Rezultati - Szarek, Michael
- Showing 1 - 20 results of 26
- Go to Next Page
-
1
-
2
-
3
-
4
Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial od Murphy, William A., Lin, Nan, Damask, Amy, Schwartz, Gregory G., Steg, P. Gabriel, Szarek, Michael, Banerjee, Poulabi, Fazio, Sergio, Manvelian, Garen, Pordy, Robert, Shuldiner, Alan R., Paulding, Charles
Izdano 2022Text -
5
Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial od Hess, Connie N., Capell, Warren H., Bristow, Michael R., Ruf, Wolfram, Szarek, Michael, Morrow, David A., Nicolau, Jose C., Graybill, Christopher A., Marshall, Debra, Hsia, Judith, Bonaca, Marc P.
Izdano 2022Text -
6
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment od Schwartz, Gregory G., Szarek, Michael, Bittner, Vera A., Bhatt, Deepak L., Diaz, Rafael, Goodman, Shaun G., Jukema, J. Wouter, Loy, Megan, Manvelian, Garen, Pordy, Robert, White, Harvey D., Steg, Philippe Gabriel
Izdano 2021Text -
7
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSE... od Schwartz, Gregory G., Steg, Philippe Gabriel, Szarek, Michael, Bittner, Vera A., Diaz, Rafael, Goodman, Shaun G., Kim, Yong-Un, Jukema, J. Wouter, Pordy, Robert, Roe, Matthew T., White, Harvey D., Bhatt, Deepak L.
Izdano 2020Text -
8
A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-risk Acute Myeloid Leukemia od Fehniger, Todd A., Miller, Jeffrey S., Stuart, Robert K., Cooley, Sarah, Salhotra, Amandeep, Curtsinger, Julie, Westervelt, Peter, DiPersio, John F., Hillman, Timothy M., Silver, Nova, Szarek, Michael, Gorelik, Leonid, Lowdell, Mark W, Rowinsky, Eric
Izdano 2018Text -
9
Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease od Szarek, Michael, Hess, Connie, Patel, Manesh R., Jones, W. Schuyler, Berger, Jeffrey S., Baumgartner, Iris, Katona, Brian, Mahaffey, Kenneth W., Norgren, Lars, Blomster, Juuso, Rockhold, Frank W., Hsia, Judith, Fowkes, F. Gerry R., Bonaca, Marc P.
Izdano 2022Text -
10
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol od Schwartz, Gregory G., Szarek, Michael, Bittner, Vera A., Diaz, Rafael, Goodman, Shaun G., Jukema, J. Wouter, Landmesser, Ulf, López-Jaramillo, Patricio, Manvelian, Garen, Pordy, Robert, Scemama, Michel, Sinnaeve, Peter R., White, Harvey D., Steg, Ph Gabriel
Izdano 2021Text -
11
Sex‐Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD od Hess, Connie N., Baumgartner, Iris, Anand, Sonia S., Nehler, Mark R., Patel, Manesh R., Debus, E. Sebastian, Szarek, Michael, Capell, Warren, Muehlhofer, Eva, Berkowitz, Scott D., Haskell, Lloyd P., Bauersachs, Rupert M., Bonaca, Marc P., Hsia, Judith
Izdano 2022Text -
12
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score–Matched Analysis of... od Schwartz, Gregory G., Gabriel Steg, Philippe, Bhatt, Deepak L., Bittner, Vera A., Diaz, Rafael, Goodman, Shaun G., Jukema, J. Wouter, Kim, Yong-Un, Li, Qian H., Manvelian, Garen, Pordy, Robert, Sourdille, Timothée, White, Harvey D., Szarek, Michael
Izdano 2021Text -
13
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients od Frankel, Arthur E., Woo, Jung H., Ahn, Chul, Pemmaraju, Naveen, Medeiros, Bruno C., Carraway, Hetty E., Frankfurt, Olga, Forman, Stephen J., Yang, Xuezhong A., Konopleva, Marina, Garnache-Ottou, Francine, Angelot-Delettre, Fanny, Brooks, Christopher, Szarek, Michael, Rowinsky, Eric
Izdano 2014Text -
14
Alirocumab after acute coronary syndrome in patients with a history of heart failure od White, Harvey D, Schwartz, Gregory G, Szarek, Michael, Bhatt, Deepak L, Bittner, Vera A, Chiang, Chern-En, Diaz, Rafael, Goodman, Shaun G, Jukema, Johan Wouter, Loy, Megan, Pagidipati, Neha, Pordy, Robert, Ristić, Arsen D, Zeiher, Andreas M, Wojdyla, Daniel M, Steg, Philippe Gabriel
Izdano 2021Text -
15
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OU... od Tuñón, José, Steg, Philippe Gabriel, Bhatt, Deepak L, Bittner, Vera A, Díaz, Rafael, Goodman, Shaun G, Jukema, J Wouter, Kim, Yong-Un, Li, Qian H, Mueller, Christian, Parkhomenko, Alexander, Pordy, Robert, Sritara, Piyamitr, Szarek, Michael, White, Harvey D, Zeiher, Andreas M, Schwartz, Gregory G
Izdano 2020Text -
16
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual antic... od Berkowitz, Scott D., Bauersachs, Rupert M., Szarek, Michael, Nehler, Mark R., Debus, E. Sebastian, Patel, Manesh R., Anand, Sonia S., Capell, Warren H., Hess, Connie N., Hsia, Judy, Leeper, Nicholas J., Brasil, David, Mátyás, Lajos, Diaz, Rafael, Brodmann, Marianne, Muehlhofer, Eva, Haskell, Lloyd P., Bonaca, Marc P.
Izdano 2022Text -
17
Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES od Jukema, J. Wouter, Zijlstra, Laurien E., Bhatt, Deepak L., Bittner, Vera A., Diaz, Rafael, Drexel, Heinz, Goodman, Shaun G., Kim, Yong-Un, Pordy, Robert, Reiner, Željko, Roe, Matthew T., Tse, Hung-Fat, Montenegro Valdovinos, Pablo Carlos, White, Harvey D., Zeiher, Andreas M., Szarek, Michael, Schwartz, Gregory G., Steg, Philippe Gabriel
Izdano 2019Text -
18
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization od Hess, Connie N., Szarek, Michael, Anand, Sonia S., Bauersachs, Rupert M., Patel, Manesh R., Debus, E. Sebastian, Nehler, Mark R., Capell, Warren H., Beckman, Joshua A., Piazza, Gregory, Henkin, Stanislav, Bura-Rivière, Alessandra, Lawall, Holger, Roztocil, Karel, Hsia, Judith, Muehlhofer, Eva, Berkowitz, Scott D., Haskell, Lloyd P., Bonaca, Marc P.
Izdano 2022Text -
19
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial od Bhatt, Deepak L., Eikelboom, John W., Connolly, Stuart J., Steg, P. Gabriel, Anand, Sonia S., Verma, Subodh, Branch, Kelley R.H., Probstfield, Jeffrey, Bosch, Jackie, Shestakovska, Olga, Szarek, Michael, Maggioni, Aldo Pietro, Widimský, Petr, Avezum, Alvaro, Diaz, Rafael, Lewis, Basil S., Berkowitz, Scott D., Fox, Keith A.A., Ryden, Lars, Yusuf, Salim
Izdano 2020Text -
20
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acu... od Roe, Matthew T., Li, Qian H., Bhatt, Deepak L., Bittner, Vera A., Diaz, Rafael, Goodman, Shaun G., Harrington, Robert A., Jukema, J. Wouter, Lopez-Jaramillo, Patricio, Lopes, Renato D., Louie, Michael J., Moriarty, Patrick M., Szarek, Michael, Vogel, Robert, White, Harvey D., Zeiher, Andreas M., Baccara-Dinet, Marie T., Steg, Ph. Gabriel, Schwartz, Gregory G.
Izdano 2019Text